Bio-Techne Corporation (NASDAQ: TECH) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | S&P 500 | P/E | 101.82 | EPS (ttm) | 0.71 | Insider Own | 1.62% | Shs Outstand | 156.57M | Perf Week | 0.28% |
| Market Cap | 11.32B | Forward P/E | 31.13 | EPS next Y | 2.32 | Insider Trans | -0.34% | Shs Float | 155.94M | Perf Month | 1.60% |
| Enterprise Value | 11.40B | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 7.77% | Perf Quarter | 42.00% |
| Income | 109.79M | P/S | 9.35 | EPS this Y | 197.46% | Inst Trans | - | Short Ratio | 2.61 | Perf Half Y | 9.76% |
| Sales | 1.21B | P/B | 5.40 | EPS next Y | 13.14% | ROA | 4.30% | Short Interest | 12.12M | Perf YTD | 22.92% |
| Book/sh | - | P/C | 38.22 | EPS next 5Y | 9.03% | ROE | 5.49% | 52W High | 72.19 -0.10% | Perf Year | 44.96% |
| Cash/sh | - | P/FCF | 41.98 | EPS past 3/5Y | -34.80% -20.52% | ROIC | 4.75% | 52W Low | 43.10 67.34% | Perf 3Y | -11.86% |
| Dividend Est. | 0.32 (0.44%) | EV/EBITDA | 44.19 | Sales past 3/5Y | 3.32% 10.55% | Gross Margin | 64.96% | Volatility | 0.29% 0.45% | Perf 5Y | -40.04% |
| Dividend TTM | 0.32 (0.44%) | EV/Sales | 9.41 | EPS Y/Y TTM | -34.29% | Oper. Margin | 12.70% | ATR (14) | 0.63 | Perf 10Y | 160.97% |
| Dividend Ex-Date | May 18, 2026 | Quick Ratio | 3.18 | Sales Y/Y TTM | 4.49% | Profit Margin | 9.05% | RSI (14) | 73.65 | Recom | 2.50 |
| Dividend Gr. 3/5Y | 0.00% 0.00% | Current Ratio | 4.49 | EPS Q/Q | 26.19% | SMA20 | 0.64% | Beta | 1.25 | Target Price | 64.88 |
| Payout | 45.47% | Debt/Eq | 0.14 | Sales Q/Q | -1.58% | SMA50 | 11.59% | Rel Volume | 1.14 | Prev Close | 72.29 |
| Employees | 3,100 | LT Debt/Eq | 0.22 | Earnings | Aug 11 | SMA200 | 20.67% | Avg Volume | 4.91M | Price | 72.12 |
| IPO Date | Feb 09, 1989 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -0.79% -1.48% | Net Debt/EBITDA | 0.31 | Volume | 5,577,377 | Change | -0.24% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-09-26 | Downgrade | RBC Capital | Outperform → Sector Perform | |
| Jun-30-26 | Downgrade | TD Cowen | Buy → Hold | |
| Jun-30-26 | Downgrade | Benchmark | Buy → Hold | |
| Jun-29-26 | Downgrade | Citigroup | Buy → Neutral | |
| Jun-26-26 | Reiterated | Robert W. Baird | $49 → $73 | |
| Jun-26-26 | Reiterated | Deutsche Bank | Buy | $72 → $73 |
| Jun-26-26 | Downgrade | Stephens & Co. | Overweight → Equal Weight | $105 → $73 |
| Jun-26-26 | Downgrade | William Blair | Outperform → Market Perform | |
| Jun-25-26 | Reiterated | Leerink Partners | $73 | |
| Jun-11-26 | Initiated | Piper Sandler | Neutral | $65 |
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 6/30/2025 | FY 2024 6/30/2024 | FY 2023 6/30/2023 | FY 2022 6/30/2022 | FY 2021 6/30/2021 | FY 2020 6/30/2020 | FY 2019 6/30/2019 | FY 2018 6/30/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,211 | 1,220 | 1,159 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 424 | 429 | 389 | — | — | — | — | — | — | |
| Gross Profit | 786 | 790 | 770 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 362 | 415 | 393 | — | — | — | — | — | — | |
| Research and Development | 96 | 99 | 97 | — | — | — | — | — | — | |
| Other Operating Expense | 175 | 174 | 73 | — | — | — | — | — | — | |
| Operating Income | 153 | 102 | 207 | — | — | — | — | — | — | |
| Interest Expense | 10 | 9 | 16 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 3 | 5 | -5 | — | — | — | — | — | — | |
| Net Income Before Taxes | 147 | 98 | 186 | — | — | — | — | — | — | |
| Income Taxes | 38 | 25 | 18 | — | — | — | — | — | — | |
| Consolidated Net Income | 109 | 73 | 168 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 109 | 73 | 168 | — | — | — | — | — | — | |
| Net Income | 109 | 73 | 168 | — | — | — | — | — | — | |
| EPS (Recurring) | 0.71 | 0.47 | 1.07 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.71 | 0.47 | 1.07 | — | — | — | — | — | — | |
| EPS (Diluted) | 0.69 | 0.46 | 1.05 | — | — | — | — | — | — | |
| EBITDA | 258 | 217 | 313 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 104.52 | 111.85 | 68.24 | — | — | — | — | — | — | |
| Price To Sales Ratio | 9.29 | 6.66 | 9.77 | — | — | — | — | — | — | |
| Gross Margin | 64.91 | 64.75 | 66.44 | — | — | — | — | — | — | |
| Operating Margin | 12.63 | 8.36 | 17.86 | — | — | — | — | — | — | |
| Net Margin | 9.00 | 5.98 | 14.50 | — | — | — | — | — | — | |
| Shares Outstanding | 156 | 158 | 158 | — | — | — | — | — | — | |
| Market Capitalization | 11,250 | 8,129 | 11,321 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Hippel James | CFO | Jul 29 '26 | Option Exercise | 47.60 | 62,068 | 2,954,437 | 215,738 | Jul 31 |
| Kelderman Kim | Chief Executive Officer | Jul 28 '26 | Option Exercise | 47.60 | 35,000 | 1,666,000 | 100,799 | Jul 30 |
| Bohnen Shane | SVP - General Counsel | Jul 23 '26 | Option Exercise | 47.60 | 448 | 21,325 | 7,697 | Jul 27 |
| Crouse Steven C. | President - Diag & Spatial Bi | Jun 02 '26 | Option Exercise | 0.00 | 600 | 0 | 6,977 | Jun 04 |
| Herr Amy E. | Director | May 08 '26 | Sale | 48.28 | 6,636 | 320,386 | 200 | May 12 |
| Herr Amy E. | Director | May 08 '26 | Option Exercise | 47.60 | 6,636 | 315,874 | 6,836 | May 12 |
| Hippel James | CFO | May 05 '26 | Option Exercise | 47.60 | 62,000 | 2,951,200 | 210,625 | May 07 |
| Bohnen Shane | SVP - General Counsel | May 05 '26 | Option Exercise | 47.60 | 8,400 | 399,840 | 14,304 | May 07 |
| Kelderman Kim | Chief Executive Officer | May 05 '26 | Option Exercise | 47.60 | 26,692 | 1,270,539 | 89,750 | May 07 |
| Crouse Steven C. | President - Diag & Spatial Bi | May 01 '26 | Option Exercise | 0.00 | 794 | 0 | 6,688 | May 05 |
| Hippel James | CFO | Apr 22 '26 | Option Exercise | 0.00 | 62,000 | 0 | 204,722 | Apr 24 |
| Kelderman Kim | Chief Executive Officer | Apr 22 '26 | Option Exercise | 0.00 | 11,344 | 0 | 64,421 | Apr 24 |
| Kelderman Kim | Chief Executive Officer | Apr 14 '26 | Option Exercise | 0.00 | 36,500 | 0 | 85,165 | Apr 16 |
| Bohnen Shane | SVP - General Counsel | Apr 03 '26 | Option Exercise | 0.00 | 2,259 | 0 | 6,644 | Apr 07 |
| Herr Amy E. | Director | Feb 17 '26 | Sale | 59.10 | 1,976 | 116,791 | 200 | Feb 19 |